Inquiry Basket
MC-Val-Cit-PAB-tubulysin5a is a drug-linker conjugate for ADC with potent antitumor activity by using tubulysin5a (a tubulin inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
| Catalog Number | Size | Price | Quantity | |
|---|---|---|---|---|
| BADC-00631 | -- | $-- | Inquiry |
MC-Val-Cit-PAB-tubulysin5a is a potent targeted drug conjugate that combines the highly cytotoxic compound tubulysin5a with a peptide linker (MC-Val-Cit-PAB). Tubulysin5a is a member of the tubulysin class of antimitotic agents, which disrupt microtubule dynamics and prevent proper cell division, leading to cancer cell death. The MC-Val-Cit-PAB linker is designed to release tubulysin5a specifically at the tumor site, minimizing its systemic toxicity and enhancing its therapeutic potential in cancer treatment. This conjugate offers a targeted approach, improving the efficacy and safety of tubulysin-based therapies.
One key application of MC-Val-Cit-PAB-tubulysin5a is in the treatment of solid tumors. Tubulysin5a's mechanism of action involves inhibition of microtubule polymerization, which effectively halts cell division and induces apoptosis in rapidly dividing tumor cells. The MC-Val-Cit-PAB linker ensures that tubulysin5a is activated only in the tumor microenvironment, where specific proteases cleave the peptide linker, releasing the drug directly at the site of cancer cells. This targeted delivery reduces off-target effects on healthy tissues and enhances the drug's antitumor activity, making it a promising approach for the treatment of solid cancers such as breast, lung, and colon cancers.
MC-Val-Cit-PAB-tubulysin5a also holds promise for overcoming drug resistance in cancer therapy. Many cancers develop resistance to conventional chemotherapies, including those targeting microtubules, through various mechanisms such as drug efflux or changes in the microtubule network. By using a targeted drug delivery system, MC-Val-Cit-PAB-tubulysin5a ensures that the cytotoxic agent is specifically delivered to the tumor cells, even in cases of resistance. This approach allows for more effective treatment of resistant cancer strains, improving therapeutic outcomes and offering a potential solution for patients with limited treatment options.
In addition, MC-Val-Cit-PAB-tubulysin5a can be utilized in combination therapies to enhance treatment efficacy. By combining tubulysin5a with other targeted therapies, such as immune checkpoint inhibitors or other chemotherapy agents, the conjugate could improve the overall therapeutic response. The specificity of the MC-Val-Cit-PAB linker ensures that tubulysin5a is only released at the site of action, while combination therapies can work synergistically to attack tumors through multiple pathways. This combination approach may reduce the likelihood of tumor relapse and improve patient survival rates.
Customer Support
Providing excellent 24/7 customer service and support
Project Management
Offering 100% high-quality services at all stages
Quality Assurance
Ensuring the quality and reliability of products or services
Global Delivery
Ensuring timely delivery of products worldwide
BOC Sciences offers comprehensive services for ADC manufacturing, including antibody modification, linker chemistry, payload conjugation, and formulation development. In particular, our payload-linker customization service offers a convenient and fast raw material channel for many ADC researchers.
BOC Sciences provides one-stop site-specific conjugation services for amino acids, glycans, unnatural amino acids, and short peptide tags. In addition, cysteine conjugation, lysine conjugation, enzymatic conjugation, thio-engineered antibody can also be obtained quickly.
BOC Sciences offers a full range of linkers, including peptide linkers, PEG linkers, click chemistry, PROTAC linkers, non-cleavable linkers, etc. We also provide custom development services for chemically labile linkers and enzymatically cleavable linkers.
